Is Living With Psychosis Demoralizing? Insight, Self-stigma, and Clinical Outcome Among People With Schizophrenia Across 1 Year by Cavelti, Marialuisa et al.
Title 
Is living with psychosis demoralizing? Insight, self-stigma and clinical outcome among people 
with schizophrenia across one year 
 
Running title 
Is living with psychosis demoralizing? 
 
Authors  
Marialuisa Caveltia, PhD, Nicolas Rüschb, Professor MD, Roland Vauthc, Professor MD 
 
a Corresponding author: University Hospital for Psychiatry, Bolligenstrasse 111, CH-3000 Bern 60, 
Switzerland. Tel: +41 930 91 11, fax: +41 930 97 61, e-mail address: marialuisa.cavelti@gef.be.ch  
b Section of Public Mental Health, Department of Psychiatry II, University of Ulm, Parkstrasse 11, D-
89073 Ulm, Germany 
c University Hospital for Psychiatry, Department of Psychiatric Outpatient Treatment, Claragraben 95, 
CH-4500 Basel, Switzerland 
 
Funding 









































  1/15 
Is living with psychosis demoralizing? Insight, self-stigma and clinical outcomes among people 
with schizophrenia across one year 
 
ABSTRACT 
Background: Lack of insight is a major target in the treatment of schizophrenia. However, insight may have 
undesirable effects on self-concept and motivation that can hinder recovery. This study aimed to examine the 
link between insight, self-stigma and demoralization as predictors of symptoms and functioning. 
Methods: Insight, self-stigma, depressive and psychotic symptoms, and functioning were assessed among 133 
outpatients with schizophrenia at baseline and twelve months later. The data were analyzed by hierarchical 
multiple linear regressions.  
Results: More insight at baseline and an increase in self-stigma over twelve months predicted more 
demoralization at follow-up. Insight at baseline was not associated with any outcome variable, but self-stigma at 
baseline was related to poorer functioning and more positive symptoms at follow-up. More demoralization at 
baseline predicted poorer functioning twelve months later. Demoralization did not mediate the relationship 
between self-stigma at baseline and functioning after one year.  
Discussion: Given the decisive role of self-stigma regarding recovery from schizophrenia, dysfunctional beliefs 
related to illness and the self should be addressed in treatment. Different psychotherapeutical approaches are 
discussed. 
Keywords: Insight, self-stigma, demoralization, recovery 
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1. Introduction 
Insight – defined as the awareness of having a mental disorder, its symptoms, consequences, and need for 
treatment – is one of the main targets in research about and treatment of schizophrenia. Lack of insight is a 
common phenomenon in schizophrenia with reported rates between 30% and 80% (Mintz et al, 2003; Lincoln et 
al., 2007). It is an established risk factor for maladherence to treatment and poor clinical outcome, such as high 
levels of positive and negative symptoms, frequent relapses and hospitalizations, and poor social and vocational 
functioning (Johnson et al., 2012; Kurtz et al., 2013; Lincoln et al., 2007; Van Baars et al., 2013). However, 
recent research showed that higher levels of insight do not have exclusively desirable effects, such as better 
treatment adherence and clinical outcome, but are also linked to more depression, hopelessness, and a greater 
suicidal tendency as well as lowered self-esteem and quality of life (Cooke et al., 2007; Drake et al., 2004; 
Lopez-Morinigo et al., 2012; Sharaf et al., 2012). The contradictory empirical findings regarding the correlates 
and consequences of insight in schizophrenia were described as “insight-paradox” (Lysaker et al., 2007).  
Examining the psychological processes underlying this paradox, insight was found to be only associated 
with negative effects when accompanied by self-stigma (Cavelti et al., 2012a, 2012b; Lysaker et al., 2007; 
Staring et al., 2009). Self-stigma results from the identification and internalization of negative public stereotypes 
about mental disorders and includes dysfunctional feelings (e.g. low self-esteem) and behavioural reactions (e.g. 
social withdrawal) among the affected persons (Corrigan and Watson, 2002). A recent review revealed high 
prevalence rates of personal stigma among people with schizophrenia: 49.2% reported alienation (shame) as the 
most common aspect of self-stigma (Gerlinger et al., 2013). Based on previous research, Yanos et al. (2010) 
proposed a theoretical model how the subjective meaning of having schizophrenia impacts recovery: For 
example, accepting a definition of oneself as mentally ill and assuming that this means being lifelong 
handicapped and becoming a socially worthless or even a dangerous person, affect hope and self-esteem, which 
further influence symptom severity, suicide risk, coping, social interactions and vocational functioning. Thus, 
insight is not just the acceptance of a single fact (e.g. the illness label or that the illness is caused by a dopamine 
dysregulation which needs antipsychotic mediation) but the integration of a range of experiences (e.g. having 
confusing experiences pretending friends to be enemies or the awareness that one is evaluated differently by 
others after a psychotic episode) into a complex personalized narrative of personal and psychiatric challenges 
(Lysaker et al., 2013b). If “being insightful” means to accept a diagnosis with detrimental consequences for 
one’s future, the negative effects found to accompany growing insight may be best described as the result of 
demoralization. Demoralization is defined as a syndrome of existential distress that can occur in individuals who 
have a chronic mental illness that threatens integrity of being or of people’s meaning of who they are as engaged 
subjects in the world (Clarke and Kissane, 2002). In sum, taking the “insight-paradox” into account while 
fostering recovery seems highly relevant: Interventions targeting insight in order to improve adherence with 
evidence-based treatments seem indicated to promote symptom remission and rehabilitation of functioning 
(Liberman et al., 2002), while demoralization as an “accidental side-effect” of growing insight may undermine 
these efforts by its detrimental effects on self-concept and motivation (Cavelti et al., 2012a). This notion is in 
line with the consumer movement who stresses the importance of accepting the diagnosis while keeping or 
regaining a positive self-concept (e.g. identity transformation from “patienthood” to “personhood”), which 
enables a meaningful and satisfying life despite the presence of the mental disorder (Davidson et al., 2005; 
Onken et al., 2007). 
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Further research is needed to better understand demoralization and its impact on recovery from severe 
mental illness. Eventually, this could enable us to define more precisely the targets of psychotherapeutic 
interventions in schizophrenia. In a recent cross-sectional study on outpatients with schizophrenia spectrum 
disorders we found insight to be related to demoralization and this link to be stronger as self-stigma increased. 
Moreover, self-stigma was associated with more psychotic symptoms and lower levels of global functioning, 
while these associations were fully mediated by demoralization (Cavelti et al., 2012b). Building on these 
findings and the literature referred to above, the aim of the current study was to confirm the supposed process of 
demoralization impeding recovery from schizophrenia with longitudinal data (see Figure 1). We tested the 
hypothesis that higher levels of insight at baseline predict higher levels of demoralization after one year. 
Additionally, this association was expected to be moderated by self-stigma, i.e. the association of insight and 
demoralization is more pronounced in patients with higher levels of self-stigma. Furthermore, we expected that 
higher levels of demoralization at baseline would increase positive and negative symptoms and worsen role 
functioning over time. Finally, we supposed demoralization to mediate the long-term associations of insight and 
self-stigma with symptoms and functioning.  
 
Please, insert Figure 1 here. 
2. Methods 
2.1. Participants and procedure 
The current study is part of a larger investigation of predictors of service engagement with community mental 
health services in persons with chronic schizophrenia and contains the longitudinal results based on the same 
sample as our cross-sectional studies (Beck et al., 2011, 2012; Cavelti et al., 2012a, 2012b; Kvrgic et al., 2013). 
Between February 2009 and March 2010 consumers of community mental health services in the region 
of Basel, Switzerland, between 18 years and 65 years of age and diagnosed with schizophrenia or schizoaffective 
disorder were recruited. Diagnoses were confirmed by the Structured Clinical Interview for Diagnostic and 
Statistical Manual of Mental Disorders - IV Axis I Disorders (First et al., 1996). Exclusion criteria were a 
primary diagnosis of alcohol or substance dependency, an organic syndrome or learning disability, inadequate 
command of German, and homelessness. After a full explanation of the study aims and procedures, participants 
provided written informed consent. The assessment consisted of an interview and questionnaires for participants 
and questionnaires for their therapists, administered at baseline (tb) and at 12-month follow-up (tf). In order to 
minimize selection bias by a high refuser rate, participants received a financial compensation of 40 CHF (Swiss 
Francs) for the baseline and of 60 CHF for the follow-up assessment. The study was approved by the local ethics 
committee. See Figure 2 for a flowchart of the study procedure.  
 
Please, insert Figure 2 here. 
2.2. Measures 
We exclusively used measures with established reliability and validity for people with severe mental illness. 
Measures available only in English were translated into German using the back-translation method (Brislin, 
1971).  
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Insight was assessed using both an observer- and a self-rated measure. The Scale to assess 
Unawareness of Mental Disorder (SUMD; Amador et al., 1993) is a semi-structured interview to evaluate global 
awareness of having a mental disorder, the achieved effects of medication, and the social consequences of 
having a mental disorder as well as specific insight into symptoms and their attribution to the mental disorder. 
These dimensions of insight were rated on a 5-point Likert scale (1=“aware” to 5=“unaware”), with higher 
scores indicating poorer awareness. The Insight Scale (IS; Birchwood et al., 1994) is a questionnaire to measure 
insight into psychiatric illness and treatment. Patients respond to eight statements with “I agree”, “I disagree”, or 
“I am unsure”. A higher total sum score indicates a higher level of insight.  
Dysfunctional beliefs about oneself as a person with schizophrenia were assessed by the subscales Self-
Concurrence and Self-Esteem Decrement of the Self-Stigma of Mental Illness Scale (SSMIS; Corrigan et al., 
2006). Each subscale contains 10 items which are rated on a 9-point Likert scale ranging from “1=strongly 
disagree” to “9=strongly agree”. The two subscales Stereotype Awareness and Stereotype Agreement were not 
considered because being aware of or agreeing with stereotypes can occur purely as a cognitive process without 
any impact of the self-concept. Instead, only when the person concurs with the stigma and experiences 
diminished self-esteem can a significant impact on the self be expected (Corrigan et al., 2006). Recent research 
showed that even the single subscale of Self-Esteem Decrement is a valid approximation of self-stigma (Rüsch et 
al., 2010).  
Recent work demonstrated that the depressive symptoms often seen in schizophrenia are related to 
patients’ perceptions of their illness and might usefully be considered as demoralization (Birchwood et al., 1993; 
Sharhar et al., 2010; Thomas et al., 2012). Thus, we included both an observer- and self-rated measure to assess 
depressive symptoms on a continuum with demoralization. The Calgary Depression Scale for Schizophrenia 
(CDSS; Muller et al., 1999) is a semi-structured interview to evaluate depressive symptoms independently of 
negative symptoms in schizophrenia. Nine items were rated on a 4-point Likert scale (0=“absent” to 
3=“severe”). A higher total sum score indicates a higher level of depression. The Beck Depression Inventory-
Revised (BDI-II; Kuhner et al., 2007) is a questionnaire consisting of 21 items, each with four statements 
indicating increasing severity (4-point Likert scale from 0 to 3). A higher total sum score indicates more 
depressive symptoms. The Emotional Regulation subscale of the Subjective Well-being under Neuroleptic 
treatment scale short-form (SWN; Naber et al., 2001) was added to guarantee that the hallmark of demoralization 
- hopelessness - was well represented (Clarke and Kissane, 2002). The four items were rated on a 6-point Likert 
scale (1=“not at all” to 6=“very much”) and added to a total score (item example: “I have no hope for the 
future”). 
Positive and negative symptoms common in schizophrenia were assessed by the Positive and Negative 
Syndrome Scale (PANSS; Kay et al., 1987). This semi-structured interview consists of 30 items to measure 
psychopathological symptoms common in schizophrenia based on a 7-point Likert scale (“1=absent”, 
“7=extreme”). We used the positive and negative syndrome factors identified by Cuesta and Peralta (1995), with 
higher scores indiciating higher levels of psychopathology. 
Role functioning was assessed by the Modified Global Assessment of Functioning scale (M-GAF; Hall, 
1995); a global observer measure of psychological, social, and occupational functioning, covering the range from 
positive mental health to severe psychopathology. A single score is rated ranging from 1-90, with higher scores 
indicating a higher level of global functioning.  
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2.3. Statistical analyses 
All statistical analyses were conducted using SPSS version 19.0. At first, to similarly consider self- and 
observer-ratings, we calculated composite scores, separately for baseline and follow-up data, and, if not normally 
distributed, applied log transformation. The insight composite scores were built by summing up the z-scores of 
the reversed total score of the IS and the two SUMD subscales, current awareness and current attribution of 
symptoms. The baseline insight composite score had to be transformed. Higher composite scores indicate lower 
levels of insight. The self-stigma composite scores consist of the sum of the two SSMIS subscales, Self-
Concurrence and Self-Esteem Decrement, and were both transformed. Higher scores reflect more negative self-
beliefs. The demoralization composite scores were calculated by summing up the z-scores of the BDI-II, the 
CDSS and the Emotional Regulation subscale of the SWN short-form, and were also both transformed. Higher 
scores indicate being more demoralized.  
Afterwards, we tested if the 133 participants who completed the study procedure (completers) differed 
from the 33 participants who dropped out between the baseline and the follow-up interviews (noncompleters) 
using one-way ANOVAs. We found no significant differences between completers and noncompleters in 
positive (F(1, 164=3.06, P=.08), negative (F(1, 164)=.41, P=.53), and depressive symptoms (F(1, 165)=1.56, 
P=.21) or in insight (SUMD Current Awareness of Symptoms: F(1, 164)=.91, P=.34; SUMD Current Attribution 
of Symptoms: F(1, 164)=.36, P=.55) at study begin. However, at baseline noncompleters (M=43.66, SD=9.71) 
showed a significantly lower level of role functioning than completers (M=50.34, SD=10.46, F(1, 165)=10.80, 
P=.00). 
Finally, hierarchical multiple linear regression analyses with the 133 completed datasets were 
conducted. Beforehand, in order to identify relevant confounders, we tested if the outcome variables at follow-up 
(demoralization, positive symptoms, negative symptoms and functioning) vary depending on sex, age, diagnosis 
(schizophrenia / schizoaffective disorder), antipsychotic medication (yes / no) and the additional intake of a 
mood stabilizer (yes / no) or an antidepressant (yes / no) using one-way ANOVAs. Therefore, the categorical 
variables were transformed using weighted effects coding, which allows comparing each of the group’s means 
with the grand mean and takes the different group sizes into account (Frazier et al., 2004). We found participants 
who took a neuroleptic medication to show lower levels of negative symptoms (M=7.09, SD=2.91) than those 
who did not (M=9.80, SD=3.56), F(1, 131)=4.11, P=.05. Furthermore, the additional intake of an antidepressant 
was found to be significantly associated with higher levels of demoralization (M=.77, respectively, M=.71, 
SD=.11, respectively, SD=.13, F(1, 131)=8.45, P=.00) and positive symptoms (M=4.73, respectively, M=3.91, 
SD=2.36, respectively, SD=2.12, F(1, 131)=4.12, P=.00) as well as lower levels of role functioning (M=47.07, 
respectively, M=52.54, SD=9.09, respectively, SD=9.12, F(1, 131)=10.62, P=.00). Sex, age, diagnosis and the 
additional intake of a mood stabilizer had no significant impact on outcome variables. Thus, antipsychotic 
medication (yes / no) and the additional intake of an antidepressant (yes / no) were considered as confounders in 
further regression analyses. We used three blocks of predictors, entering one after another. The first block 
considered the confounding variable, the second block the dependent variable at baseline (tb) and the third block 
the predictor variable(s) at baseline (tb). The contribution of each block to the explained outcome variance was 
examined by testing the difference in F-scores on significance (∆F, P). If the block does not significantly 
contribute to the amount of explained outcome variance, the coefficients should not be further interpreted 
(Frazier et al., 2004).  
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2.3.1. Moderator analysis 
In order to test the moderator hypothesis, a product term (insight*self-stigma) was created to represent the 
interactions between the predictor (insight) and the moderator (self-stigma) by multiplying the standardized (i.e. 
z-scored) forms of these variables assessed at baseline. Before multiplying, a constant term was added to the z-
scores in order to guarantee that all z-scores are positive. Running the regression analysis, the standardized 
predictor and moderator variables assessed at baseline were entered in the third step, followed by the product 
term in the fourth step (Frazier et al., 2004).  
2.3.2. Mediator analysis 
In a two-wave longitudinal design, two paths have to be estimated in order to test mediation: First, the path from 
the predictor variable at baseline (Xb) to the mediator variable at follow-up (Mf) while controlling for the 
mediator variable at baseline (Mb); and second, the path from the mediator variable at baseline (Mb) to the 
outcome variable at follow-up (Yf) while controlling for the outcome variable at baseline (Yb). The product of 
the two paths represents an estimation of the mediation (or indirect) effect of Xb on Yf (Cole and Maxwell, 
2003). The significance of the indirect effect was tested by dividing the product of the two paths from Xb to Mf 
(f) and from Mb to Yf (g) by the standard error term proposed by Kenny and colleagues (1998) (√g2sf2 + f2sg2 + 
sf2sg2; where f and g are unstandardized regression coefficients and sf and sg are their standard errors). The 
mediated effect divided by its standard error yields a z-score of the mediated effect. If the z-score is greater than 
1.96, the mediation effect is significant at the .05 level. The 95% confidence interval around the estimate of the 
indirect effect were calculated by the product of the paths f and g +/- sfgz.975, where z.975 is equal to the 
constant 1.96 and sfg is the standard error term calculated earlier. Mediation is confirmed, if the confidence 
interval does not include zero (Frazier et al., 2004). 
3. Results 
3.1. Sample characteristics  
Of the 133 completers, 47 (35.4%) were female. The mean age at study begin was 44.48 years (SD=11.88). The 
majority lived alone (n=73; 54.9%) and had neither a stable partnership (of at least three months duration, 
n=102; 76.7%) nor children (n=98; 73.7%). On average, they received 12.34 years of education (SD=2.98). Most 
participants were unemployed (neither on the free nor on the protected market) (n=71; 53.4%) and received a 
governmental disability annuity (n=100; 75.2%). Eighty-nine participants (66.9%) were diagnosed with 
schizophrenia and 44 (33.1%) with schizoaffective disorder. On average, participants had been mentally ill since 
18.06 years (SD=12.05) and treated in the community mental health services since 6.89 years (SD=6.21). The 
majority (n=128; 96.2%) received an antipsychotic medication, usually at least one second-generation agent 
(n=122; 91.7%). In addition to the antipsychotic medication, twenty-two participants (16.5%) received a mood 
stabilizer and 44 participants (33.1%) an antidepressant.  
Table 1 contains reliability scores, means and standard deviations of the variables at baseline and 
follow-up as well as the significances of the mean differences tested by t-tests for dependent samples. Notably, 
while the awareness of symptoms rated by researchers improved, the attribution of symptoms rated by 
researchers and general insight rated by patients decreased over the study period.   
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Please, insert Table 1 here. 
 
3.2. One-year predictors of demoralization  
We found higher levels of insight at baseline to significantly predict more demoralization at follow-up (see Table 
2, Model 1). Self-stigma at baseline was not a significant predictor of demoralization twelve months later (see 
Model 2). In an additional analysis we tested if the difference of the self-stigma scores at baseline and at follow-
up (Mtf-Mtb) impacted demoralization at follow-up. Due to the failure to the normality assumption, the log-
transformed score was used. We found an increase in self-stigma to be significantly associated with higher levels 
of demoralization at follow-up (see Model 3). A further regression analysis was run with insight at baseline and 
the self-stigma difference score as simultaneous predictors of demoralization at follow-up. The significant 
influence of both predictors (insight: B(SE)=-.01(.00), β=-.16, P=.05; self-stigma difference: B(SE)=.91(.37), 
β=.20, P=.02) on demoralization at follow-up remained stable (R2=.22, ∆R2=.06, ∆F=5.09, P=.01). To facilitate 
the interpretation of these results, we repeated the regression analysis separately for patients with an increase 
(n=51; 38.3%) and those with no change or a decrease (n=82; 71.7%) in self-stigma during the follow-up period. 
An increase in self-stigma from baseline to follow-up was significantly associated with higher levels of 
demoralization at follow-up (B(SE)=1.75(.85), β=.27, P=.05, R2=.19, ∆R2=.07, ∆F=4.22, P=.05), while no 
change or a decrease in self-stigma scores from baseline to follow-up did not significantly predict demoralization 
twelve months later (R2=.17, ∆R2=.01, ∆F=.89, P=.35). Finally, to test self-stigma as a moderator of the 
association between insight and demoralization over one year, we used the self-stigma difference score instead 
of self-stigma at baseline which was not confirmed as a significant predictor of demoralization at follow-up. The 
product variable “insight at baseline x self-stigma difference score” failed to significantly impact demoralization 
at follow-up (see Model 4). Thus, self-stigma did not moderate the association between insight at baseline and 
demoralization one year later.  
 
Please, insert Table 2 here. 
 
3.3. One-year predictors of clinical outcome  
Higher levels of demoralization at baseline were linked to lower levels of role functioning at follow-up (see 
Table 3, Model 3). The associations of demoralization at baseline with positive and negative symptoms twelve 
months later were not significant (see Models 1 and 2).  
In order to examine the hypothesis that demoralization mediates the associations of insight and self-
stigma at baseline with outcome variables at follow-up, we firstly tested the direct impact of insight and self-
stigma at baseline on symptoms and role functioning twelve months later. Insight at baseline did neither 
significantly predict symptom severity (positive symptoms: R2=.46, ∆R2=.00, ∆F=.17, P=.68; negative 
symptoms: R2=.26, ∆R2=.00, ∆F=.24, P=.63), nor level of role functioning (R2=.36, ∆R2=.00, ∆F=.12, P=.73) at 
follow-up. Higher levels of self-stigma at baseline were significantly associated with more positive symptoms 
(B(SE)=1.96(.73), β=.17, P=.05, R2=.69, ∆R2=.03, ∆F=7.14, P=.01) and lower levels of role functioning at 
follow-up (B(SE)=-7.12(.3.44), β=-.15, P=.04, R2=.38, ∆R2=.02, ∆F=4.30, P=.04), but were not significantly 
linked to negative symptoms twelve months later (R2=.26, ∆R2=.01, ∆F=1.07, P=.30). Testing the indirect effects 
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of insight and self-stigma at baseline on outcome variables at follow-up requires significant associations of the 
mediator variable (e.g. demoralization) with the outcome variables (e.g. symptoms and role functioning). Since 
this was exclusively found for role functioning, the mediation analyses were only conducted with role 
functioning as dependent variable. However, neither the indirect effect from insight to role functioning (z-
score=1.37 < 1.96), nor the indirect effect from self-stigma to role functioning (z-score=1.37 < 1.52) were 
statistically significant, falsifying demoralization as a mediator of the relationship between insight or self-stigma 
at baseline and role functioning one year later.  
 
Please, insert Table 3 here. 
4. Discussion 
4.1. Discussion of the results 
The aim of the current study was to examine the demoralization process as an obstacle to recovery from 
schizophrenia. As expected, we found higher levels of insight to predict more demoralization twelve months 
later. This result confirms our previous cross-sectional work (Cavelti et al., 2012b) and is consistent with 
findings on insight’s negative consequences (Cooke et al., 2007; Drake et al., 2004; Lopez-Morinigo et al., 2012; 
Sharaf et al., 2012). In previous studies self-stigma was used to resolve the “insight-paradox”; the contradictory 
finding that insight can be associated with both positive and negative outcomes (Cavelti et al., 2012a, 2012b; 
Lysaker et al., 2007; Staring et al., 2009). According to this idea, insight is related to negative outcomes when 
dysfunctional stereotypes of mental illness are internalized and to positive outcomes when they are rejected. 
Although we found an increase in self-stigma during the observation period to predict more demoralization at 
follow-up, we failed to confirm self-stigma as a moderator of the insight-demoralization-link. Several reasons 
may contribute to this unexpected result: Firstly, to the best of our knowledge, this is the first study having 
examined the associations of insight, self-stigma and aspects of the demoralization syndrome using longitudinal 
data. Thus, it may be that the moderator effect of self-stigma found in cross-sectional studies does not hold over 
time. Secondly, there are other studies which also failed to find a moderation effect of self-stigma (Sharaf et al., 
2012; Yanos et al., 2008). There is some evidence from cross-sectional research that the relationships of insight, 
self-stigma and aspects of demoralization may be better explained by a mediation model than a moderator model 
(Cavelti et al., 2012b; Hasson-Ohayon et al., 2009, 2011). According to a mediation model, insight increases 
aspects of demoralization by increasing self-stigma. Finally, the insight-demoralization-link could be moderated 
by other, unconsidered factors than self-stigma, such as the experience of real failure at school or work, and the 
withdrawal of family and friends. 
In our study, insight at baseline did not significantly predict symptoms or role functioning twelve 
months later. This result is in contrast to other studies which demonstrated the relevance of insight for good 
clinical outcome (e.g. Kurtz et al., 2013; Van Baars et al., 2013) and may be due to the specific characteristics of 
our sample. We examined people with a long history of illness and treatment and none (negative symptoms and 
functioning) or small (positive symptoms) change in clinical parameters over the study period (see Table 1). 
However, we found higher levels of self-stigma at baseline to lead to more positive symptoms, such as delusions 
and hallucinations, and poorer role functioning at follow-up. These results confirm our cross-sectional findings 
(Cavelti et al., 2012b) and are in line with the growing evidence that self-stigma can contribute to the 
exacerbation of psychotic symptoms and deterioration of daily functioning (Lysaker et al., 2007; Munoz et al., 
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2011; Yanos et al., 2008, 2010). According to the social cognitive model of self-stigma (Corrigan and Watson, 
2002), internalizing the negative expectations about mental illness may be a source of internal stress which 
triggers psychotic symptoms and interferes with a person’s self-efficacy, eventually undermining motivation for 
daily performance (Rüsch et al., 2009a, 2013b). For example, individuals may fail to pursue work or an 
independent living opportunity not (only) because of illness-based disabilities but because of the internalized 
societal belief that persons with mental illness are not capable of achieving valued social roles and do not 
deserve a satisfying life. And this may be even true for people without insight into their illness: In our clinical 
practice, we see patients who do not believe they have schizophrenia, but feel that the diagnostic label makes it 
difficult for them to pursue their life goals (e.g. a young woman opposed the diagnosis because she feared to be 
barred from education as a nursery school teacher).  
Finally, we found higher levels of demoralization at baseline to also predict poorer role functioning 
twelve months later, but failed to confirm demoralization as a mediator of the adverse relationship between self-
stigma at baseline and role functioining at follow-up. Maybe the detrimental impact of self-stigma on 
functioning is mediated by other, unconsidered variables, such as symptom severity or self-efficacy (Cavelti et 
al., 2012b; Hill and Startup, 2013; Kurtz et al., 2013).  
4.2. Clinical implications 
People with severe mental illness do not suffer only from symptoms and functional impairments, but also from 
damages on self-concept and future prospects resulting from the negative implications of the illness label and/or 
the real experience of losses in life (e.g. withdrawal of family and friends, vocational impairment). Our findings 
highlight the importance of considering both in treatment of schizophrenia: symptoms and functioning as well as 
the subjective meaning of living with psychosis. If the second aspect is neglected, efforts to promote recovery 
may be doomed. For example, the treatment of psychotic symptoms by an antipsychotic medication or cognitive-
behavioural techniques may fail because the patient does not feel she or he is worthy to try (Corrigan et al., 
2009). 
Along with psychological models of psychosis (Garety et al., 2001), psychological strategies to cope with 
symptoms and impairments have been developed during the last years (e.g. cognitive behavioural or acceptance 
methods for persistent hallucinations and delusions). In contrast, treatment approaches considering the 
demoralization process are just at their beginnings. Mittal et al. (2012) recently reviewed the literature about 
interventions to reduce self-stigma among people with mental illness and identified two prominent approaches. 
The first approach includes psycho-educational and cognitive strategies to alter the stigmatizing beliefs and 
attitudes of the individual. It regards self-stigma as the result of maladaptive self-statements or cognitive 
schemata of mental illness which may be altered by normalizing, exploring distressing cognitions about the self, 
attempting to reframe them as beliefs rather than facts, empathically discussing how one might arrive at such 
beliefs (but also recognizing their emotional costs), reviewing evidence for and against the beliefs, and trying to 
find less distressing alternative interpretations. The second approach encourages the acceptance of stigmatizing 
stereotypes without challenging them (e.g. acceptance and commitment therapy) and enhances skills for coping 
with self-stigma through improvements in self-esteem, empowerment, and help-seeking behaviour. Recently, 
Rüsch and colleagues (2013a) developed Coming Out Proud as a manualized peer-led group intervention on 
weighing the risks and benefits of secrecy versus disclosure in different setting. The program’s goal is to enable 
people with mental illness to decide whether or not to disclose and thus to reduce stigma’s negative impact. 
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Another promising approach to reduce self-stigma is narrative enhancement (Lysaker et al., 2010; Roe et al., 
2010). In contrast to the cognitive approach of challenging dysfunctional beliefs about the self and replacing one 
belief with another, narrative enhancement aims at impoverished senses of self and help people to create a richer 
personal narrative of who one is in the world in which stigmatizing beliefs are not dominant. Based on the 
assumption of the onset of a severe mental illness as a disruption in one’s autobiography, the final aim is to 
integrate the experience of the mental illness in one’s life story, to fill the void left by negative and damning self-
appraisals and to develop a perspective on the future, which is no longer dominated by hopelessness and 
resignation but includes the opportunity of a meaningful life despite the mental illness. The mutual creation of 
stories of human lives together with awareness of stigma as unjust might evoke righteous anger and 
empowerment in life and personal growth. This approach goes in line with the growing amount of psychotherapy 
researchers who emphasize that all successful psychotherapy entails the articulation, revision, and deconstruction 
of clients’ maladaptive life stories in favour of more life-enhancing alternatives. Because narratives and 
emotions interact to form meaning and sense of self, the evocation and articulation of emotions is critical to 
changing life narratives (Agnus, 2012). 
4.3. Limitations and conclusion 
There are some strengths and limitations to the study which are important to consider. The strengths include the 
longitudinal design which permits causal inferences, the large sample size, the use of established assessments 
and the consideration of both self- and observer-rated instruments for insight and indicators of demoralization. 
The importance of the latter is confirmed by the differences found in insight ratings (see Table 1). However, the 
following short-comings were identified: First, the present study mixes demoralization and depression, which 
share symptoms of distress but differ with regard to subjective incompetence and helplessness in the former and 
anhedonia in the latter (Clarke and Kissane, 2002). However, there is empirical evidence that depressive 
symptoms seen in people with schizophrenia are related to patients’ perceptions of their illness and might 
usefully be considered as aspects of a demoralization syndrome (Birchwood et al., 1993; Sharhar et al., 2010). 
For example, Thomas et al. (2012) recently investigated forty persons with a diagnosis of schizophrenia and 
found that depressive symptoms were correlated with rumination, while controlling for positive and negative 
symptoms. The content of rumination frequently focused on mental illness and its causes and consequences, in 
particular social disability and disadvantage. Depressive symptoms were predicted by awareness of the social 
consequences of mental illness, an effect that was mediated by rumination. Second, the present study rests 
entirely on deliberate, explicit responses to questions in interviews or questionnaires. However, automatically 
activated, “implicit” responses may be equally important for the association of insight and negative outcome in 
schizophrenia (Rüsch et al., 2009b, 2010). Third, this study did not consider other, probably important factors 
with impact on demoralization in schizophrenia, such as the experience of real losses in life, the traumatic effect 
of involuntary treatment (Rüsch et al., 2013c) or the depressive effect of symptoms including voices to harm or 
shame the individual (Trower et al., 2004). Furthermore, this study is also uninformative about factors which 
may protect from demoralization in schizophrenia. For example, Lysaker et al. (2013a) found that participants 
diagnosed with schizophrenia with high insight but mild depression demonstrated greater levels of metacognitive 
mastery and emotion regulation than a group with insight and more severe depression and a group without 
insight or depression. These differences persisted when controlling for neurocognition and symptom severity and 
suggest that bolstering metacognitive and social cognitive capacities may have a protective effect as persons 
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achieve insight. In fact, in a recent study Kukla and colleagues (2013) found that persons with schizophrenia 
with better metacognitive skills also had greater levels of self-perceived recovery. Thus, the capacity for 
metacognition as the ability to form complex representations of oneself and others seems important for the 
construction of a meaningful account of what has happened as a result of the illness and the formulation of a way 
to adapt to the constraints imposed by schizophrenia and achieve an acceptable quality of life. Finally, because 
we forced self-stigma to be a predictor of demoralization and clinical outcome, we cannot exclude the possibility 
that the opposite relationship or a constant day-to-day interaction process is (also) true. For example, patients 
with more severe symptoms and functional disabilities may consequently feel more demoralized and, therefore, 
be more vulnerable to self-stigma. Future research should address this alternative hypothesis, for example by 
using structural equation modelling which allows the simultaneous testing of competing hypotheses.  
 In sum, in our one-year oberservational study we found partial support for the demoralization 
hypothesis in outpatients with schizophrenia spectrum disorders: Insight into illness and an increase in self-
stigma independently contributed to a syndrome of demoralization after one year which was associated with 
poorer functioning, but not with symptoms of psychosis. Furthermore, self-stigma also predicted poorer 
functioning and more psychotic symptoms. But we failed to demonstrate that demoralization mediates the 
detrimental effect of self-stigma on clinical outcome. These results support the idea that the poor prognosis 
attributed to schizophrenia is not only a consequence of psychiatric disability and symptoms of the illness, but is 
also affected by the ways individuals experience living with psychosis and integrate these experiences into a 
personalized narrative of the challenges of  a serious psychiatric illness as the basis of reacting to and coping 
with it. Both aspects should be addressed in treatment settings. While different treatment approaches including 
cognitive, behavioural, accepting, and narrative strategies have been developed, more intervention studies are 
needed to better understand the differential effects and the underlying mechanisms of change on a psychological 
and neurobiological level.  
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Figure 1. Model of the demoralizing process in schizophrenia: Direct and indirect influences of insight and self-





































Figure 2. Progress of recruitment and data collection. 


































Table 1. Cronbach’s alpha coefficients (α), means (M) and standard deviations (SD) of variables at baseline  
(tb) and follow-up (tf) and the significances of the mean differences (P) 
Notes. IS=Insight Scale, SUMD=Scale to assess Unawareness of Mental Disorder, BDI=Beck Depression 
Inventory-Revised, CDSS=Calgary Depression Scale for Schizophrenia, SWN=Subjective Well-bing under 
Neuroleptic treatment scale, SSMIS=Self-Stigma of Mental Illness Scale, PANSS=Positive And Negative 
Syndrome Scale, M-GAF=Modified Global Assessment of Functioning. 
a 
reversed scored; higher scores indicate lower levels of insight 
Variable αtb Mtb (SDtb) αtf Mtf (SDtf) T (df) P 
IS .71 9.5 (2.42) .73 9.3 (2.56) 1.04 (132) .30 
SUMD Current Awareness of Symptomsa - 2.16 (1.29) - 2.61 (1.4) -3.28 (132) .00 
SUMD Current Attribution of Symptomsa - 2.81 (1.34) - 2.34 (1.11) 3.86 (132) .00 
BDI-II total score .90 11.05 (9.61) .88 9.53 (8.39) 2.18 (132) .03 
CDSS total score .78 3.47 (3.64) .66 3.37 (4.13) .27 (132) .79 
SWN short-form Emotional Regulation .68 17.33 (4.56) .56 18.42 (3.99) -2.75 (132) .01 
SSMIS Self-Concurrence .74 26.11 (11.2) .82 25.44 (12.9) .68 (132) .50 
SSMIS Self-Esteem Decrement .84 25.46 (13.41) .85 23.42 (12.98) 1.90 (132) .06 
PANSS Positive Syndrome .74 4.59 (2.59) .63 4.18 (2.23) 2.40 (132) .02 
PANSS Negative Syndrome .69 7.39 (3.14) .52 7.19 (2.97) .73 (132) .46 
M-GAF - 50.35 (10.46) - 50.73 (9.44) -.47 (132) .64 
 Table 2. Hierarchical multiple linear regression analyses with the demoralization composite score at  
follow-up as dependent variable 
Model Blocks B (SE) β R2 ∆R2 ∆F 
1 1 Antidepressant tb  .04 (.01) .26** .07 .07 9.21** 
 2 Antidepressant tb 











 3 Antidepressant tb 
Demoralization Composite Score tb 







.18 .03 3.91* 
2 1 Antidepressant tb .04 (.01) .26** .07 .07 9.21** 
 2 Antidepressant tb 





.15 .09 13.27*** 
 3 Antidepressant tb 
Demoralization Composite Score tb 







.17 .02 2.85 
3 1 Antidepressant tb  .04 (.01) .26** .07 .07 9.21** 
 2 Antidepressant tb  











 3 Antidepressant tb  
Demoralization Composite Score tb 







.19 .04 6.00* 
4 1 Antidepressant tb .04 (.01) .26** .07 .07 9.21** 
 2 Antidepressant tb  





.15 .09 13.27*** 
 3 Antidepressant tb  
Demoralization Composite Score tb 
Insight Composite Score tb1  









.22 .07 5.46** 
 4 Antidepressant tb  
Demoralization Composite Score tb 
Insight Composite Score tb1 
Selfstigma Composite Score ∆ tf-tb 











.23 .01 1.26 
Notes. tb=baseline, tf=follow-up, 1=a higher score indicates a lower level of insight, *P<.05, **P<.01,  
***P<.001  
 Table 3. Hierarchical multiple linear regression analyses with the outcome variables at follow-up as dependent 
variables 
Outcome 
variable Blocks B (SE) β R
2
 ∆R2 ∆F 
Positive 
symptoms tf 
1 Antidepressant tb  .55 (.27) .17* .03 .03 4.12* 
 2 Antidepressant tb 











 3 Antidepressant tb 
Positive symptoms tb  







.46 .00 .73 
Negative 
symptoms tf 
1 Neuroleptic tb  -.10 (.04) -.17** .03 .03 4.11* 
 2 Neuroleptic tb  





.25 .22 38.91*** 
 3 Neuroleptic tb  
Negative symptoms tb  







.25 .00 .10 
Functioning tf 1 Antidepressant tb  -3.66 (1.12) -.27** .08 .08 10.62** 












 3 Antidepressant tb  
Functioning tb 







.38 .02 4.37* 
Notes. tb=baseline, tf=follow-up, *P<.05, **P<.01, ***P<.001 
 
 
 
